OncLive TV

Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.

Ruben A. Mesa, MD, discusses mitigating racial disparities in myeloproliferative neoplasm clinical trials.

Kami J. Maddocks, MD, discusses treatment considerations for treatment selection in follicular lymphoma.

Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Monica Balzarotti, MD, discusses remaining questions regarding consolidation and maintenance therapy in relapsed/refractory diffuse large B-cell lymphoma.

Jeanne M. Palmer, MD, discusses the current treatment landscape of acute graft-versus-host disease.

Shannon N. Westin, MD, MPH, discusses challenges with precision medicine in endometrial cancer. 

Neal D. Shore, MD, FACS, discusses challenges with androgen deprivation therapy in recurrent prostate cancer.

Othman Al-Sawaf, MD, discusses new safety signals with venetoclax plus obinutuzumab in the phase 3 CLL14 trial.

Elaine Shum, MD, discusses consulting patients with non-small cell lung cancer on the use of osimertinib.

Shaji K. Kumar, MD, discusses treatment discontinuation in the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Hatem Soliman, MD, discusses the rationale for using immunotherapy in triple-negative breast cancer.

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Paul J. Shaughnessy, MD, discusses challenges with CAR T-cell therapy in relapsed/refractory hematologic malignancies.

Michael Wang, MD, discusses the safety profile of ​the CAR T-cell therapy brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

Mansoor Raza Mirza, MD, discusses the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.

Toni K. Choueiri, MD, discusses current and emerging treatment options for patients with metastatic renal cell carcinoma.

David R. Gandara, MD, discusses the impact of immunotherapy on the tumor microenvironment in lung cancer.

Madappa Kundranda, MD, PhD, discusses the need ​to develop novel treatments in pancreatic ductal adenocarcinoma.

Ruben A. Mesa, MD, discusses the potential utility of CAR T-​cell ​therapy in myeloproliferative neoplasms.

Neal D. Shore, MD, FACS, discusses unique challenges in nonmetastatic castration-resistant prostate cancer.

Jeanne M. Palmer, MD, discusses common complications associated with acute graft-versus-host disease.

Saad ​Z. Usmani, MD, FACP, discusses the key takeaways from the randomized phase 2 SWOG 1211 trial in patients with newly diagnosed, high-risk multiple myeloma.

Ruth O’Regan, MD, discusses biomarkers of response to CDK4/6 inhibitors in breast cancer.

Gary K. Schwartz, MD, discusses the updated design of the phase 2 Alliance A091401 trial for metastatic sarcomas.

Hung Khong, MD, discusses antiestrogen and immunotherapy combinations in ER-positive, HER2-negative breast cancer.

Nilanjan Ghosh, MD, PhD, discusses the utility of lisocabtagene maraleucel in relapsed/refractory non-Hodgkin lymphoma.

Joshua K. Sabari, MD, discusses the need for additional biomarkers of response to immunotherapy in driver-negative advanced non–small cell lung cancer.

Christina L. Roland, MD, PhD, discusses the rationale for a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Paul J. Shaughnessy, MD, discusses the promising future of CAR T-cell therapy in relapsed/refractory hematologic malignancies.